MSDs cost trillions; are we targeting the wrong culprit? · The Monday Briefing, 19 October 2026

October 19, 2026  ·  Weekly Newsletter

Musculoskeletal disorders (MSDs), such as osteoarthritis and back pain, continue to challenge healthcare systems by prioritizing symptom management over root cause resolution. This week's edition of The Life Science Feed examines why current approaches remain reactive, often sidelined by reimbursement models that favor treatment over prevention. The cost is steep: trillions of dollars per year globally. It's a cycle that keeps turning.

1. **MSD Management Dilemma**: The reliance on symptomatic treatment for MSDs persists despite their escalating burden on health systems. It matters.

2. **Kidney Biomarkers in Question**: Urinary exosomes are emerging as potential biomarkers for kidney disease. But standardization issues keep them out of guidelines like KDIGO. Clinicians noticed.

3. **Hidden Pregnancy Pain**: Musculoskeletal pain during pregnancy is often overlooked, impacting maternal well-being. That gap is closing.

The thread connecting this week's findings is a shared oversight of root causes in favor of symptomatic relief. MSDs, kidney disease, and pregnancy-related pain each illustrate how current medical practices can miss the mark by not addressing foundational issues. The evidence suggests a need for a paradigm shift toward more holistic and preventive care models.

Clinicians should consider looking beyond symptoms to address underlying causes, improving outcomes and reducing long-term costs. I read every reply.

Osteoarthritis

Musculoskeletal disorders (MSDs), including conditions like osteoarthritis and back pain, place an enormous and often underestimated burden on global health systems and economies, costing trillions of dollars annually. Despite this, current approaches frequently focus on reactive symptom management rather than proactive prevention and addressing underlying causes. This reactive paradigm, often incentivized by existing reimbursement models, contributes to suboptimal patient outcomes and rising…

Joint ACTRIMS-ECTRIMS 2026 Toronto Oct 21 – 23, 2026 Our page →

ESMO 2026 Madrid Oct 23 – 27, 2026 Our page →

ACR 2026 Orlando Nov 6 – 11, 2026 Our page →